SAN FRANCISCO, Oct. 8 /PRNewswire/ -- Deloitte Recap LLC (Recap) has launched the first two products in the Recap IQ Series by Deloitte, a new subscription service that provides analytical tools built on rich databases tailored toward business development, corporate strategy, financial, legal, tax and R&D professionals. Each product within the series is designed around specific biopharmaceutical research needs to offer the right business intelligence tools for the job.
"The powerful combination of IQ Series products enables users to observe leading practices in drafting an alliance and evaluating different deal structures," said Mark Edwards, president, Deloitte Recap LLC. "Subscribers can compare deals objectively to identify critical deal terms, including market rates for royalties, transfer prices and profit splits."
The first two complementary modules of the Recap IQ Series by Deloitte are "Deal Builder" and "Valuation Analyzer," which can either be purchased separately or bundled together. "Deal Builder" is a comprehensive, fully searchable database of 30,000 biopharma and related alliances covering the past three decades, including 24,000 U.S. Securities and Exchange Commission (SEC)-filed contracts.
"Valuation Analyzer" provides access to the Recap Effective Royalty Rate (EFR) Grapher, a tool used to perform real-time searches of more than 1,500 unredacted biopharma alliances. Recap has obtained unredacted copies of these contracts via Freedom of Information Act (FOIA) requests made to the SEC. By combining this unique database with EFR analysis, Recap has pioneered the objective analysis of post-launch deal structures.
"As alliance activity continues to accelerate in the Life Sciences industry, the launch of 'Deal Builder' and 'Valuation Analyzer' helps provide Deloitte Recap subscribers of the Recap IQ Series by Deloitte with a timely resource to evaluate their alliance strategies supported by the latest industry data," said Terry Hisey, vice chairman and Life Sciences Industry Leader, Deloitte LLP. "Since the acquisition of Recombinant Capital, Inc. last July, Deloitte has worked to develop these new solutions and services to provide subscribers with flexible tools built on rich data sources."
"The Recap IQ Series by Deloitte provides users a one-stop-shopping experience for identifying the latest trends in biopharmaceutical alliance formation, as well as developing strategies for execution," said Mike McCully, senior manager, Deloitte Recap LLC. "Deloitte will continue to develop new modules to complete the series over the next year to further enhance the suite of solutions and services available to subscribers."
Originally founded as Recombinant Capital, Inc. in 1988 by Mark Edwards and based in the San Francisco Bay Area. In July 2008, Recombinant Capital, Inc. was purchased by a subsidiary of Deloitte LLP and the business is now known as Deloitte Recap LLC (Recap). Please see www.recap.com for more information about Recap's services. As used in this document, "Recap" means Deloitte Recap LLC and "Deloitte" means Deloitte LLP and Deloitte Services LP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.
CONTACT: Marykate Reese Public Relations Deloitte +1 203 257 0452 email@example.com
Copyright©2009 PR Newswire.
All rights reserved